• AAPL 192.32
  • TSLA 239.37
  • AMZN 144.52
  • BTC-USD 43958.1875
  • ETH-USD 2247.658
  • EURUSD 1.0762
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. MRUS.US

Merus BV (MRUS NASDAQ) stock market data APIs

$24.02 -0.76(-3.1%) as of December 6, 2023

Merus BV Financial Data Overview

24.78
24.02
-
24.955
23.81
12.44-27.7
1 429 M
57 733 K
45 674 K
-0.43
0
0.821
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'MRUS',
Type: 'Common Stock',
Name: 'Merus BV',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00B8LXMS5',
ISIN: 'NL0011606264',
CUSIP: 'N5749R100',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2016-05-19',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
GicSector: 'Health Care',
GicGroup: 'Pharmaceuticals, Biotechnology & Life Sciences',
GicIndustry: 'Biotechnology',
GicSubIndustry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Merus BV Fundamental Data is available in our Financial Data APIs

  • Net Revenue 45 674 K
  • EBITDA -160 434 000
  • Earnings Per Share -3.72
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Merus BV Earnings via APIs

  • Latest Release 2023-11-02
  • EPS/Forecast -0.73

Get Merus BV End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Merus BV latest news via APIs

Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade

Investors might want to bet on Merus N.V. (MRUS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock pr...

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

Merus N.V. MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: ...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com